# Rituximab in Interstitial Pneumonitis

> **NCT02251964** · PHASE2,PHASE3 · COMPLETED · sponsor: **Human Adams** · enrollment: 20 (estimated)

## Conditions studied

- Lung Diseases, Interstitial
- Pneumonitis, Interstitial

## Interventions

- **DRUG:** Rituximab
- **RADIATION:** Zr-89-rituximab immuno PET/CT

## Key facts

- **NCT ID:** NCT02251964
- **Lead sponsor:** Human Adams
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-10
- **Final completion:** 2018-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2018-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02251964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02251964, "Rituximab in Interstitial Pneumonitis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02251964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*